Welcome to our dedicated page for Cingulate SEC filings (Ticker: CINGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cingulate Inc. (CINGW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Cingulate files a range of documents with the U.S. Securities and Exchange Commission that together outline its financial condition, capital structure, governance, and progress in developing its Precision Timed Release™ (PTR™) platform and lead ADHD candidate, CTx-1301.
Among the most relevant filings for CINGW are Form 10-Q quarterly reports and Form 10-K annual reports, which detail operating expenses such as research and development and general and administrative costs, net losses, cash and working capital levels, and accumulated deficit. These reports also discuss key milestones, including the submission and FDA acceptance of the New Drug Application (NDA) for CTx-1301 under the 505(b)(2) pathway and the assignment of a Prescription Drug User Fee Act (PDUFA) target action date.
Cingulate’s Form 8-K current reports are especially important for tracking material events. Recent 8-Ks describe unregistered sales of equity securities, executive and board changes, the submission of the CTx-1301 NDA, and the announcement of quarterly financial results via press release. Other filings, such as Form NT 10-Q, explain delays in periodic reports and reference management transitions, while the DEF 14A proxy statement for a special meeting outlines stockholder votes on equity issuance under a purchase agreement with Lincoln Park Capital.
For investors focused on the CINGW warrants and capital structure, filings like the Form S-1/A registration statement and related 8-Ks provide detail on committed equity facilities, warrant listings, and share issuances to lenders or service providers. On Stock Titan, these filings are updated in near real time from EDGAR, and AI-powered summaries help explain complex sections, such as equity financing terms, executive compensation arrangements, and risk disclosures, so users can more quickly interpret how each document may affect Cingulate’s development and financing plans.
Director Jeffrey S. Ervin of Cingulate has been granted 15,000 stock options on June 20, 2025. The options have the following key terms:
- Exercise price set at $4.14 per share
- Expiration date of June 20, 2035 (10-year term)
- Vesting occurs at the earlier of:
- One-year anniversary of grant date
- Date of Cingulate's 2026 annual stockholder meeting
This Form 4 filing represents a standard director compensation grant, with the options providing Ervin the right to purchase common stock at the specified strike price. The grant aligns the director's interests with shareholders through long-term equity incentives.
Director John A. Roberts of Cingulate was granted 15,000 stock options on June 20, 2025. The stock options have the following key terms:
- Exercise price set at $4.14 per share
- Expiration date of June 20, 2035 (10-year term)
- Vesting occurs at earlier of: - One-year anniversary of grant date - Date of Cingulate's 2026 annual stockholder meeting
This Form 4 filing, signed by Attorney-in-Fact Shane J. Schaffer on June 23, 2025, represents standard non-employee director equity compensation. The options provide Roberts with the right to purchase up to 15,000 shares of Cingulate common stock once vested. This grant aligns the director's interests with those of shareholders through long-term equity ownership potential.
Director Peter J. Werth of Cingulate received a stock option grant for 15,000 shares of common stock on June 20, 2025. The options were granted with an exercise price of $4.14 per share and will expire on June 20, 2035.
Key terms of the option grant:
- Vesting occurs at the earlier of: one-year anniversary of grant date or the 2026 annual stockholder meeting
- Transaction reported as a Form 4 filing indicating changes in beneficial ownership
- Options were acquired at no cost ($0) as part of director compensation
The filing was signed by Shane J. Schaffer as attorney-in-fact on June 23, 2025. This equity grant appears to be part of standard director compensation arrangements and represents a new beneficial ownership position for the reporting person.